Cargando…
Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
The limited effectiveness of current therapies against Alzheimer’s disease (AD) highlights the need for intensifying research efforts devoted to developing new agents for preventing or retarding the disease process. During the last few years, targeting the endogenous cannabinoid system has emerged a...
Autores principales: | Aso, Ester, Ferrer, Isidre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942876/ https://www.ncbi.nlm.nih.gov/pubmed/24634659 http://dx.doi.org/10.3389/fphar.2014.00037 |
Ejemplares similares
-
CB(2) Cannabinoid Receptor As Potential Target against Alzheimer's Disease
por: Aso, Ester, et al.
Publicado: (2016) -
Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer’s Disease
por: Uddin, Md. Sahab, et al.
Publicado: (2020) -
Impact of the Cannabinoid System in Alzheimer's Disease
por: Li, Shuangtao, et al.
Publicado: (2023) -
Promoter Hypermethylation of the Phosphatase DUSP22 Mediates PKA-Dependent TAU Phosphorylation and CREB Activation in Alzheimer's Disease
por: Sanchez-Mut, Jose Vicente, et al.
Publicado: (2014) -
In situ structural characterization of early amyloid aggregates in Alzheimer’s disease transgenic mice and Octodon degus
por: Benseny-Cases, Núria, et al.
Publicado: (2020)